Check out the latest scientific presentations from Kailera Therapeutics.

June 2025

Efficacy and Safety of a Novel Oral Small Molecule Glucagon Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin
L. Guo et al.
American Diabetes Association (ADA) 2025

June 2025

Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks
J. Zhao et al.
American Diabetes Association (ADA) 2025

June 2025

Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA in Chinese Obese Adults without Diabetes
W. Gu et al.
American Diabetes Association (ADA) 2025

June 2025

Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes: Up to 52-Week Treatment
L. Zhao et al.
American Diabetes Association (ADA) 2025

June 2025

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants: A Phase 1 Study
W. Hu et al.
American Diabetes Association (ADA) 2025

June 2025

Efficacy and Safety of a Novel Dual GLP-1/GLP Receptor Agonist in Chinese Overweight or Obese Adults without Diabetes
J. Zhou et al.
American Diabetes Association (ADA) 2025

September 2024

Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor agonist, in Patients with Type 2 Diabetes Mellitus (T2DM): A Phase 2 Trial
J. Zhao et al.
European Association for the Study of Diabetes (EASD) 2024

June 2024

Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Obese Adults: A Phase 2 Trial
L. Zhao et al.
American Diabetes Association (ADA) 2024

December 2023

Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist HRS9531 in T2DM patients: A Randomized, Double-blind, Placebo and Open-label Positive-controlled Phase 1b Trial
L. Zhao et al.
International Diabetes Federation (IDF) 2023

June 2023

Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose (SAD and MAD) Study
K. He et al.
American Diabetes Association (ADA) 2023

June 2023

Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-Ascending Dose (SAD and MAD) Study
J. Wu et al.
American Diabetes Association's (ADA) 2023